Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20155645 | 0.82 | — | — | |
| SCHEMBL23375202 | 0.79 | KIF11 (0.30) | — | |
| SCHEMBL24026540 | 0.68 | SMN1; SMN2 (0.39) | CYP3A4 | |
| SCHEMBL19088696 | 0.68 | KIF11 (0.32) | — | |
| SCHEMBL22757310 | 0.67 | CYP19A1 (0.40) | — | |
| SCHEMBL22096425 | 0.66 | ALDH1A1 (0.40) | CYP3A4 | |
| SCHEMBL25718495 | 0.65 | — | — | |
| SCHEMBL25996323 | 0.65 | — | — | |
| SCHEMBL1702353 | 0.64 | HMGCR (0.30) | — | |
| SCHEMBL19705982 | 0.62 | KIF11 (0.36) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220508-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11174265-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220508-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CYP17A1 1617/4885CYP3A4 4404/4885CYP2C9 4115/4885 |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP17A1 1617/4885CYP3A4 4404/4885CYP2C9 4115/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP17A1 1617/4885CYP3A4 4404/4885CYP2C9 4115/4885 |
| US-11174265-B2 | — | TYK2, JAK2, JAK1 | CYP17A1 1258/4885CYP3A4 4576/4885CYP2C9 4571/4885 |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CYP17A1 1617/4885CYP3A4 4404/4885CYP2C9 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.